Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition-Reference-Cited by-同舟云学术

Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition

Published:2018-10-30 Issue:46 Volume:115 Page:E10810-E10811
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proc Natl Acad Sci USA

Author:

Kawakami Masanori,Mustachio Lisa Maria,Zheng Lin,Chen Yulong,Rodriguez-Canales Jaime,Mino Barbara,Kurie Jonathan M.,Roszik Jason^ORCID,Villalobos Pamela Andrea,Thu Kelsie L.,Silvester Jennifer,Cescon David W.,Wistuba Ignacio I.,Mak Tak W.,Liu Xi,Dmitrovsky Ethan

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference6 articles.

1. CFI-400945 is not a selective cellular PLK4 inhibitor

2. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

3. Reversible centriole depletion with an inhibitor of Polo-like kinase 4

4. Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent

5. The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms;Leukemia;2023-12-19

2. Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma;Nature Communications;2023-03-18

3. Keep Calm and Carry on with Extra Centrosomes;Cancers;2022-01-17

4. Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells;Journal of Cancer Research and Clinical Oncology;2020-08-08

5. PLK4: a promising target for cancer therapy;Journal of Cancer Research and Clinical Oncology;2019-09-06